9 completed, 4 recruiting, 1 active not recruiting, 1 terminated. 16 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 9, Recruiting 4, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Recruiting 2, Active not recruiting 1 |
Follow Acute Undifferentiated Leukemia: new trials by email Literature Review of Acute Undifferentiated Leukemia trials Research Report on Acute Undifferentiated Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Ossium Health, Inc. | 2022-09-01 | 2026-02-24 | |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Florida | 40 | 2022-08-16 | 2026-09-01 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Syndax Pharmaceuticals | 30 | 2022-03-09 | 2024-08-13 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia GTI-2040, pharmacological study, laboratory biomarker analysis - Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2007-03-01 | 2015-12-04 |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes ispinesib, laboratory biomarker analysis, pharmacological study - Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-12-01 | 2013-01-11 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia tanespimycin - Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2004-03-01 | 2013-06-05 |
| Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia allopurinol, cyclophosphamide, daunorubicin hydrochloride - Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 302 | 2003-06-01 | 2022-05-03 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction imatinib mesylate, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 2001-08-01 | 2013-02-07 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
Leukemia, Biphenotypic, Acute (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Leukemia, Myeloid, Acute (12) · Blast Crisis (6) · Leukemia, Myelomonocytic, Chronic (6) · Burkitt Lymphoma (5) · Hodgkin Disease (5) · Intraocular Lymphoma (5) · Leukemia, Hairy Cell (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Large-Cell, Anaplastic (5) · Lymphoma, T-Cell, Cutaneous (5) · Mycosis Fungoides (5) · Sezary Syndrome (5)
Hemic and Lymphatic Diseases (16) · Immune System Diseases (16) · Immunoproliferative Disorders (16) · Leukemia, Lymphoid (16) · Lymphatic Diseases (16) · Lymphoproliferative Disorders (16) · Neoplasms (16) · Neoplasms by Histologic Type (16) · Hematologic Diseases (15) · Leukemia, Myeloid (13) · Bone Marrow Diseases (12) · Leukemia (12) · Chronic Disease (11) · Disease Attributes (11) · Pathologic Processes (11)
Filgrastim (4) · Cyclophosphamide (3) · Cytarabine (3) · Mycophenolic Acid (3) · Vincristine (3) · Whole-Body Irradiation (3) · fludarabine (3) · fludarabine phosphate (3) · Bone Marrow Transplantation (2) · Dexamethasone (2) · Granulocyte Colony-Stimulating Factor (2) · Imatinib Mesylate (2) · Mesna (2) · Methotrexate (2) · Stem Cell Transplantation (2)
National Cancer Institute (NCI) (8) · Fred Hutchinson Cancer Center (3) · Ossium Health, Inc. (2) · Syndax Pharmaceuticals (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · University of Florida (1)
United States (15) · Canada (3) · Australia (1) · Italy (1)
Adam Lamble, MD (1) · Brenda Cooper (1) · Brenda Weigel (1) · David Maloney (1) · Elizabeth Krakow (1) · John Deeken (1) · Jordan Milner, MD (1) · Mark Kirschbaum (1) · Maryam Fouladi (1) · Naveed Ali, MD (1) · Nicole McNeer, MD, PhD (1) · Ramesh Ramanathan (1) · Richard Aplenc (1) · Wendy Stock (1)
PMID 22259028, PMID 23393050, PMID 24474568, PMID 32499241, PMID 36402456, PMID 38683966
U01CA062505 (3), U01CA097452 (3), U01CA062502 (2), P01CA078902 (1), P30CA015704 (1), U01CA062487 (1), U01CA062491 (1), U01CA099168 (1), U01CA121947 (1), U10CA031946 (1)